抄録
BCG-CWS was administered in 30 patients with primary lung cancer, and in most cases this was in conjunction with other therapeutic procedures such as irradiation, chemotherapy and/or surgery.
Oil-attached BCG-CWS was prepared by homogenizing 4mg of BCG-CWS, two drops of mineral oil and 2ml of 0.2% Tween 80 saline.
Two hundred μg of BCG-CWS was injected intradermally every week. In patients with carcinomatous pleuritis, 400μg of BCG-CWS was injected into the pleural cavity every week.
Prolonged survival periods in advanced lung cancer cases treated with BCG-CWS was observed in comparison with historical controls. Most of the patients showed increased PPD skin reaction and increased in vitro PHA response after BCG-CWS administration.
As adverse reactions, minimal skin ulceration was observed in 37% of the patients, and fever in 57% after repeated intradermal injection of BCG-CWS, none of which necessitated the interruption of immunotherapy. No serious side effects, however, have been observed during the BCG-CWS treatment.
